Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 2, 2010

Phylogica Taps Isogenica’s In Vitro Display Technology

  • Australian-based biopharmaceutical company Phylogica will use Isogenica’s CIS display technology to optimize the performance of three of its lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

    CIS display, an in vitro display technology, allows the generation of polypeptide libraries of unprecedented size and complexity, according to Isogenica. It is then possible to select polypeptides with high affinity and specificity for most targets, the company continues.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.